SCHEDULE 13G/A: MSD Partners and Affiliates Divest Entire Stake in Alaunos Therapeutics, Reporting Zero Beneficial Ownership

MSD Partners, MSD Credit Opportunity Master Fund, and Gregg R. Lemkau have filed an Amendment No. 5 to Schedule 13G, disclosing that they no longer beneficially own any shares of Alaunos Therapeutics, Inc. common stock.

Summary

• This document is Amendment No. 5 to Schedule 13G, jointly filed by MSD Partners, L.P., MSD Credit Opportunity Master Fund, L.P., and Gregg R. Lemkau.
• The filing reports that as of December 31, 2024, the aforementioned reporting persons collectively hold 0% beneficial ownership of Alaunos Therapeutics, Inc.'s common stock.
• This amendment signifies a complete divestment of their previously held stake in Alaunos Therapeutics, Inc.
• The reporting persons certify that the securities were not acquired or held for the purpose of, or with the effect of, changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The filing indicates that MSD Partners and its affiliates have reduced their beneficial ownership in Alaunos Therapeutics, Inc. to 0%, signifying a complete divestment of their stake. This action by a notable investment group is typically viewed negatively by the market, as it suggests a lack of confidence or a strategic exit.

Negatives

• The reporting entities (MSD Partners, MSD Credit Opportunity Master Fund, and Gregg R. Lemkau) have reduced their beneficial ownership in Alaunos Therapeutics, Inc. to 0%.
• This indicates a complete divestment of their stake, which could be interpreted as a lack of confidence or a strategic exit by a significant investor.

Future Outlook

NA

Industry Context

This filing reflects a specific investment firm's portfolio adjustment, indicating their decision to exit a position in Alaunos Therapeutics, Inc., a company in the biotechnology or pharmaceutical sector (implied by 'Therapeutics'). It does not provide broader industry trends.

Stakeholder Impact

• Shareholders: The divestment by a significant institutional investor could lead to negative market sentiment and potentially impact the share price.

Key Dates

Keywords

Alaunos Therapeutics, MSD Partners, MSD Credit Opportunity Master Fund, Gregg R. Lemkau, Schedule 13G, beneficial ownership, common stock, divestment, SEC filing, investment management